| 引用本文: |
冀卓然,王曼,郝明霞,李茜荣,寇小妮.化肝汤对原发性肝癌患者经TACE和RFA治疗预后的影响[J].湖南中医药大学学报,2022,42(12):2077-2082[点击复制] |
|
| |
|
|
| 本文已被：浏览 1411次 下载 899次 |
| 化肝汤对原发性肝癌患者经TACE和RFA治疗预后的影响 |
| 冀卓然,王曼,郝明霞,李茜荣,寇小妮 |
| (陕西中医药大学, 陕西 咸阳 712000;陕西中医药大学附属医院, 陕西 咸阳 712000) |
| 摘要: |
| 目的 观察化肝汤对原发性肝癌患者经TACE和RFA治疗预后的影响。方法 系统性回顾分析2016年2月至2021年5月在陕西中医药大学附属医院肝病医院的120例原发性肝癌患者资料,按照不同的治疗方法分别分为观察组与对照组:对照组A(35例)单纯经TACE治疗,观察组A(36例)经TACE治疗后给予中药化肝汤治疗;对照组B(25例)单纯经RFA治疗,观察组B(24例)经RFA治疗后服用中药化肝汤治疗。统计经TACE治疗和RFA治疗的两种不同局部治疗方法治疗前后的临床疗效评价、中医证候积分、肝功能血清生化指标[谷丙转氨酶(alanine aminotransferase, ALT)、谷草转氨酶(aspartate aminotransferase, AST)]、血清肿瘤标记物指标甲胎蛋白(alpha-fetoprotein, AFP)及术后卡氏功能状态评分(karnofsky performance score, KPS),并比较4组患者经治疗后两年内的生存情况。结果 经治疗后,观察组总有效率显著高于对照组(P<0.05);4组治疗后的ALT、AST、AFP水平均较治疗前降低,且观察组均低于对照组(P<0.05);4组治疗后的中医证候积分均较治疗前下降,且观察组均低于对照组(P<0.05);4组治疗后的KPS评分也较治疗前显著升高,且观察组均高于对照组(P<0.05);观察组的2年生存率均高于对照组(P<0.05)。结论 化肝汤对改善原发性肝癌患者经TACE和RFA治疗的预后有明显作用,可有效提高患者的生存质量,有效延长患者的生存期。 |
| 关键词: 原发性肝癌 化肝汤 介入术 射频消融术 临床疗效 预后 |
| DOI：10.3969/j.issn.1674-070X.2022.12.019 |
| 投稿时间：2022-06-28 |
| 基金项目:陕西省科技厅社会发展领域项目(2018SF295) |
|
| Effects of Huagan Decoction on prognosis of patients with primary liver cancer treated with TACE and RFA |
| JI Zhuoran,WANG Man,HAO Mingxia,LI Xirong,KOU Xiaoni |
| (Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China;The Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China) |
| Abstract: |
| Objective To observe the effects of Huagan Decoction on the prognosis of patients with primary liver cancer(PLC) treated with transcatheter arterial chemoembolization(TACE) and radiofrequency ablation(RFA).Methods We conducted a systematic review to 120 medical records of PLC patients in Liver Hospital of Shaanxi University of Chinese Medicine from February 2016 to May 2021, and divided them into observation group and control group according to the different therapies: control group A(35 patients) was treated with TACE alone, and study group A(36 patients) was treated with Huagan Decoction after TACE; control group B(25 patients) was treated with RFA alone, and observation group B(24 patients) was treated with Huagan Decoction after RFA. Then we analyzed the clinical efficacy evaluation, TCM syndrome scores, alanine aminotransferase(ALT),aspartate aminotransferase(AST), alpha-fetoprotein(AFP) and Kanofsky performance score(KPS) before and after the different treatments with TACE and RFA, and compared the survival conditions of four groups within two years.Results After treatment, the total efficacy rates of the observation group was significantly higher than that of the control group(P<0.05). The levels of ALT, AST and AFP in four groups after treatment were lower than those before, and the levels in the observation group were lower than those in the control group(P<0.05); the TCM syndrome scores in the observation group were improved compared with those in the control group(P<0.05); the KPS scores of the four groups after treatment were higher than those before treatment, and the KPS score of the observation group was higher than that of the control group(P<0.05); the 2-year survival rate of the observation group was higher than that of the control group.Conclusion Huagan Decoction can significantly improve the prognosis of PLC patients treated with TACE and RFA, effectively improve the quality of life and prolong the survival time of patients. |
| Key words: primary liver cancer Huagan Decoction interventiional therapy radiofrequency ablation clinical efficacy prognosis |
|
二维码（扫一下试试看！） |
|
|
|
|
